Skip to main content

6Node page

what any key link opens

psx:substance/hyoscyamus-niger/issue/notice@f56c8fd9c2e6

issue2026-09-04recordcurrent

derived from · upstream

  • derived_fromRevision 2psx:substance/hyoscyamus-niger/version/2

feeds · downstream

none recorded

Closure of psx:substance/hyoscyamus-niger/issue/notice@f56c8fd9c2e6: 55 upstream, 89 downstream.

psx:substance/hyoscyamus-niger/issue/notice@f56c8fd9c2e6
├─ derived_from  version/2  Revision 2
  ├─ used  src/doi:10.1007/s13659-022-00357-w  Beauty of the beast: anticholinergic tropane alkaloids in therapeutics
  ├─ used  src/pmid:25386392  Black henbane and its toxicity - a descriptive review
  ├─ used  src/pmid:16175141  Pharmacokinetics and pharmacodynamics in clinical use of scopolamine
  ├─ used  src/pmid:2762223  Pharmacokinetics and oral bioavailability of scopolamine in normal subjects
  ├─ used  src/doi:10.1371/journal.pone.0247688  Nixing the nightshades: Traditional knowledge of intoxicating members of the Solanaceae among hallucinogenic plant and mushroom users in Slovenia
  ├─ used  src/doi:10.1080/15563650.2020.1854281  A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome
  ├─ used  src/doi:10.3390/life13091913  Teodorico Borgognoni's Formulary for Thirteenth Century Anesthetic Preparations
  ├─ used  src/doi:10.1016/j.jep.2016.05.009  An ethnomedicinal survey of a Tashelhit-speaking community in the High Atlas, Morocco
  ├─ used  src/doi:10.1211/0022357991772808  Medicinal Plants and Alzheimer's Disease: from Ethnobotany to Phytotherapy
  ├─ used  src/doi:10.1093/pcp/pcx165  Localization and Organization of Scopolamine Biosynthesis in Duboisia myoporoides R. Br.
  ├─ used  src/doi:10.1016/j.toxicon.2020.02.005  Common anticholinergic solanaceaous plants of temperate Europe - A review of intoxications from the literature (1966-2018)
  ├─ used  src/doi:10.1016/j.heliyon.2024.e38856  Ultrasound-assisted extraction of scopolamine and hyoscyamine from Hyoscyamus niger roots using central compost design
  ├─ used  src/doi:10.1038/s41598-018-36156-y  Targeted expression of Vitreoscilla hemoglobin improves the production of tropane alkaloids in Hyoscyamus niger hairy roots
  ├─ used  src/doi:10.1007/s10529-013-1426-9  Production of tropane alkaloids in Hyoscyamus niger (black henbane) hairy roots grown in bubble-column and spray bioreactors
  ├─ used  src/pmid:29911833  Cloning and characterization of an aromatic amino acid aminotransferase (ArAT) gene involved in tropane alkaloid biosynthesis from Hyoscyamus niger
  ├─ used  src/pmid:3569262  Purification and characterization of hyoscyamine 6 beta-hydroxylase from root cultures of Hyoscyamus niger L.
  ├─ used  src/doi:10.1038/s41586-020-2650-9  Biosynthesis of medicinal tropane alkaloids in yeast
  ├─ used  src/doi:10.3920/QAS2013.0314
  ├─ used  src/pmid:979798  Henbane chewing
  ├─ used  src/doi:10.2903/j.efsa.2013.3386  Scientific Opinion on Tropane Alkaloids in Food and Feed
  ├─ used  src/pmid:11144994  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers
  ├─ used  src/pmid:8711457  Serious plant poisonings in Switzerland 1966-1994. Case analysis from the Swiss Toxicology Information Center
  ├─ used  src/doi:10.1111/jnc.15244  Tardive neurotoxicity of anticholinergic drugs: A review
  ├─ used  src/doi:10.3389/fphar.2012.00069  An Overview of the Evidence and Mechanisms of Herb-Drug Interactions
  ├─ used  src/doi:10.1080/15563650.2018.1485154  Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center
  ├─ used  src/doi:10.1007/s13181-014-0452-x  The Use of Physostigmine by Toxicologists in Anticholinergic Toxicity.
  ├─ used  src/pmid:18787311  Determination of hyoscyamine and scopolamine in serum and urine of humans by liquid chromatography with tandem mass spectrometry
  ├─ used  src/doi:10.1016/j.forsciint.2023.111678  Detection of scopolamine in urine and hair in a drug-facilitated sexual assault
  ├─ derived_from  gen/f78f6a42-ab38-4362-8d76-da6d7d502fc2  Generation — pipeline-v5
  ├─ generated_by  pub/d78cf342-0b09-4c99-8eb8-031231902795  Publication — backfill
    ├─ used  search/aec4f497-6897-4ff0-890e-2fd65d186950  Searched PubMed for "Hyoscyamus niger review pharmacology alkaloids"
    ├─ used  search/2005f989-44ae-4fc6-aa5b-295d7b52e0e6  Searched PubMed for "Hyoscyamus niger scopolamine hyoscyamine tropane alkaloids concentration"
    ├─ used  search/335687e3-f838-4d51-86d1-a1d13143613e  Searched OpenAlex for "Hyoscyamus niger phytochemistry pharmacology"
    ├─ used  search/31ea3da2-7ec7-4ba2-9640-69fd2f308301  Searched PubChem for "scopolamine"
    ├─ used  search/eeffdba4-20d4-4e4a-9ad9-d41ef53ec077  Searched PubChem for "hyoscyamine"
    ├─ used  search/13723ef7-7df9-413b-a42a-f79cf93f38ed  Searched PubChem for "atropine"
    ├─ used  search/535cbabb-b63f-4e1d-9476-22c04ec544e6  Searched PubMed for "henbane Hyoscyamus niger anticholinergic poisoning delirium hallucination"
    ├─ used  search/876ac875-bd2c-4664-a0bc-dc2b22949a6d  Searched PubMed for "scopolamine pharmacokinetics bioavailability half-life human"
    ├─ used  search/e067cf19-a800-4cfe-b0ff-f118bf55f604  Searched POWO - Plants of the World Online for "Hyoscyamus niger taxonomy"
    ├─ used  search/caab0c96-32ef-47b6-80bb-b408f7e1074d  Searched Erowid for "Hyoscyamus niger legal status"
    ├─ used  search/90253c47-7374-40a9-b536-7df9bf28fd1f  Searched USDA Forest Service for "Hyoscyamus niger history traditional use"
    ├─ used  search/15f2a727-b607-491b-88fe-bb5b5cb4630b  Searched PMC - PubMed Central for "Hyoscyamus niger alkaloid content toxic dose"
    ├─ used  search/5f6546ad-1be4-4150-8ec9-0b8ac565c3d1  Searched Google for "Hyoscyamus niger legal status Europe UK Germany France scheduled controlled"
    ├─ used  search/574eb083-7507-47e2-8fd0-0f8b7d5623b9  Searched Google for "Hyoscyamus niger history ancient Rome Vikings beer brewing"
    ├─ used  search/de9316ca-3f75-40a2-8132-cfd3d77398d4  Searched PubMed for "Henbane chewing PMID 979798"
    ├─ used  search/e5873134-f175-47ad-ba4a-57bcc6dd9100  Searched PubMed for "scopolamine detection urine hair PMID 37030199"
    ├─ used  search/06c17a58-106f-492e-96d9-66037ab931ec  Searched PubMed for "scopolamine anticholinergic tolerance dependence withdrawal"
    ├─ used  search/bb78497b-c6ee-4fa3-94a7-1e4654872b7b  Searched DOI verification - Crossref for "DOI 10.1016/j.toxicon.2020.02.005 and 10.2903/j.efsa.2013.3386"
    ├─ used  search/632c4777-bbbb-4bd5-b2d9-c77812c46526  Searched Multiple for "Alkaloid content comparison across H. niger plant sources"
    ├─ used  search/6c20a049-c9db-4163-8981-901545859749  Searched WebSearch for "Hyoscyamus niger Australia legal status"
    ├─ used  search/f9ebb44e-906d-475a-a8a9-a21e3f44b5d8  Searched WebSearch for "Hyoscyamus niger noxious weed invasive status US states Canada"
    ├─ used  search/953c5333-2920-433f-ab1c-ca7aa70b1f6e  Searched PMC/PubMed for "Teodorico Borgognoni anesthetic preparations medieval henbane PMID 37763316"
    ├─ used  search/dd607204-a876-427f-bd61-be1f50ab66b6  Searched OpenAlex for "Hyoscyamus niger henbane history traditional medicine ethnobotany"
    └─ used  search/27f32cb1-1534-4e5a-9acc-9f73a3b61606  Searched Multiple primary sources cross-reference for "Synthesis of H. niger safety, dose, and toxicology data"
  ├─ derived_from  issue/info_card@1fb004e05d18  Issued info_card
  ├─ derived_from  issue/emergency@e2acd002694f  Issued emergency
  ├─ derived_from  issue/info_card@dc0cc18f30b2  Issued info_card
  ├─ derived_from  issue/emergency@202c57e4fe57  Issued emergency
    ├─ used  claim/0409f7b7-6369-4fdc-ba17-1446b9210bb1  Claim in summary — supported
    ├─ used  claim/ff6b43e0-705b-41ee-b193-47d874412ef6  Claim in safety — supported
    ├─ used  claim/520a5e56-9295-44d5-953f-a29840a14d81  Claim in alkaloid-profile — inconclusive  working
    ├─ used  claim/adf0c5ba-32ae-408f-b4ea-e687c2cea19d  Claim in alkaloid-profile — inconclusive  working
    ├─ used  claim/25f4311e-4f42-4a89-819c-689d66d30f19  Claim in neuroscience — supported
    ├─ used  claim/8a40ceb6-a3be-439a-998a-5780c0fc9866  Claim in neuroscience — inconclusive  working
    ├─ used  claim/e4d19a4a-8473-4b95-8238-c812af96e012  Claim in summary — inconclusive  working
    ├─ used  claim/b4fd18d6-c721-4bdb-9bdb-f0ee13df150d  Claim in summary — inconclusive  working
    ├─ used  claim/668b9e28-2133-4f10-933c-331945673780  Claim in alkaloid-profile — inconclusive  working
    ├─ used  claim/f4f4bc81-6c3c-4b00-871e-1c4ef4cf0200  Claim in safety — supported
    ├─ used  claim/478feb08-eb95-45d7-ba53-66defd647898  Claim in safety — inconclusive  working
    ├─ used  claim/793d8554-34ed-4082-bef4-30498c9fb64c  Claim in safety — supported
    ├─ used  claim/dd19104c-368e-4250-854c-97b9abd32e22  Claim in safety — inconclusive  working
    ├─ used  claim/41e64c67-cc5c-4b9b-b0fe-24cc933bb0b8  Claim in safety — supported
    ├─ used  claim/697132c0-84dd-42fb-aead-7a9f55419d45  Claim in safety — inconclusive  working
    ├─ used  claim/53dd22f1-bebf-4a52-bc45-0db5bf446bd1  Claim in safety — inconclusive  working
    ├─ used  claim/6d49181c-9c03-4fda-80c6-c46159708eb2  Claim in safety — inconclusive  working
    ├─ used  claim/16f4d50e-0608-411e-9757-66cec0d38af6  Claim in safety — inconclusive  working
    ├─ used  claim/0e98cf14-87d9-4cbe-a1d7-cefc42eec31c  Claim in alkaloid-profile — inconclusive  working
    ├─ used  claim/0e91e550-3e87-4e20-bde1-40f250d64d90  Claim in preparations — inconclusive  working
    ├─ used  claim/1ea52b83-2687-4697-aa6e-0a7cef072108  Claim in preparations — inconclusive  working
    ├─ used  claim/d88a8d8e-b51f-4471-b538-8f518b147758  Claim in preparations — inconclusive  working
    ├─ used  claim/05e4a32c-b14d-47f5-86df-25134cca880c  Claim in preparations — inconclusive  working
    ├─ used  claim/50d0df36-c140-42b9-853c-ed1229361fd6  Claim in preparations — inconclusive  working
    ├─ used  claim/038a56aa-5546-4947-8b20-75d8cc00ea19  Claim in preparations — inconclusive  working
    ├─ used  claim/54b6acb4-935a-402a-a363-599fcb607cf5  Claim in neuroscience — inconclusive  working
    ├─ used  claim/fd65c32d-511f-4cc9-9f9c-36ce0ab55116  Claim in safety — inconclusive  working
    ├─ used  claim/0c3c4c87-1324-4589-8140-61d2b5609cb9  Claim in summary — inconclusive  working
    ├─ used  claim/69cbc108-e9b4-4178-848d-34c510e8b924  Claim in preparations — supported
    ├─ used  claim/4c01e62a-469d-427f-9922-b8715afbba88  Claim in safety — inconclusive  working
    ├─ used  claim/e011b0e5-5a7e-4db1-8f62-20b7482ca603  Claim in safety — inconclusive  working
    ├─ used  claim/fbccaa15-a9f9-4c20-8cd6-da60769dce8d  Claim in history — inconclusive  working
    ├─ used  claim/73393eb6-0aa3-42a9-87d2-59a1afaf55c8  Claim in neuroscience — supported
    ├─ used  claim/047d0afb-07d2-41cb-9994-3cc53899ac94  Claim in neuroscience — supported
    ├─ used  claim/38b15535-8781-4424-99e4-026ec21bb40f  Claim in neuroscience — inconclusive  working
    ├─ used  claim/7b348540-75c5-4209-a57d-ae558de9ecd7  Claim in neuroscience — inconclusive  working
    ├─ used  claim/eac4026f-295e-4696-8f2c-5c36be0b5b59  Claim in neuroscience — inconclusive  working
    ├─ used  claim/9e766c12-5062-4fbd-9da4-3d7cbfb15256  Claim in summary — partially_supported
    ├─ used  claim/e02a7b28-5558-45ce-9548-f950e40f3efe  Claim in neuroscience — supported
    ├─ used  claim/7439bed2-0bea-4d2c-8d55-b7b7b55ec623  Claim in summary — inconclusive  working
    ├─ used  claim/6288e4a4-b9b7-4324-b7ec-1686eb31db95  Claim in safety — inconclusive  working
    ├─ used  claim/e3195d41-4771-4b8a-901e-cbe3c7d6de98  Claim in summary — supported
    ├─ used  claim/6196b6b0-78c3-491a-9e7c-4391f665918d  Claim in safety — inconclusive  working
    ├─ used  claim/e9f7ff21-d470-4a7d-9945-d986d7f9c3b0  Claim in safety — supported
    ├─ used  claim/2e362c09-a955-4043-97c0-90b3172187a8  Claim in history — supported
    ├─ used  claim/aa5bf4d4-317d-41b3-8950-db4a91163769  Claim in history — supported
    ├─ used  claim/15fe493c-90be-4345-a6aa-fa1526467ca6  Claim in botanical-overview — supported
    ├─ used  claim/65c310bb-ef60-44ab-a380-5551be329885  Claim in safety — supported
    ├─ used  claim/3b29acca-3040-4ece-9221-e6f2bf727827  Claim in safety — inconclusive  working
    ├─ used  claim/fb1109e8-209d-4e38-a03d-e3585cf44e8c  Claim in botanical-overview — supported
    ├─ used  claim/356706c9-d967-47ac-be71-c6a0064b1214  Claim in alkaloid-profile — supported
    ├─ used  claim/202be00b-49df-443d-911d-5856ae7ff552  Claim in alkaloid-profile — supported
    ├─ used  claim/b4bfce64-79c2-4949-ab5f-1fcc7d8122b5  Claim in alkaloid-profile — supported
    ├─ used  claim/a8cd1ce8-b759-4a5a-a53e-ee1be571d44d  Claim in alkaloid-profile — supported
    ├─ used  claim/c5c0e87d-b97b-48fd-a82a-73ab13c2cc61  Claim in alkaloid-profile — supported
    ├─ used  claim/02d3c8d0-5926-405f-b9be-31fcf50d5b9c  Claim in alkaloid-profile — supported
    ├─ used  claim/a02b053e-618a-4be0-b180-5dabe81aff7b  Claim in alkaloid-profile — inconclusive  working
    ├─ used  claim/c065e278-209a-44bc-84a4-f5fd2043bc00  Claim in alkaloid-profile — supported
    ├─ used  claim/1c0aa753-9d0c-43b3-b097-79a1a28ad64b  Claim in safety — inconclusive  working
    ├─ used  claim/8c5c9dc0-c545-419e-a15c-b705a4b21f3e  Claim in preparations — inconclusive  working
    ├─ used  claim/2bf572dd-67da-4213-a271-f36620de7806  Claim in preparations — supported
    ├─ used  claim/55c09a15-29f9-49a7-a543-1730256b6174  Claim in safety — supported
    ├─ used  claim/1d774aae-726a-41d7-911d-4a9ebbf24b8f  Claim in preparations — supported
    ├─ used  claim/2fa1fe59-1487-4697-ab54-48cda6e2aadd  Claim in safety — supported
    ├─ used  claim/2e0be07d-6326-4010-a15a-3acb94e436c6  Claim in safety — inconclusive  working
    ├─ used  claim/fb275f07-e17c-4190-95c2-2deb36fceca5  Claim in safety — inconclusive  working
    ├─ used  claim/e4faa4b0-250f-49da-9b48-fdd4152e96e5  Claim in preparations — inconclusive  working
    ├─ used  claim/fde9a88e-755e-45fb-958a-141481a64761  Claim in neuroscience — inconclusive  working
    ├─ used  claim/02dd3877-84a5-4078-9441-e4f9df111379  Claim in safety — supported
    ├─ used  claim/51c33a85-3f48-49a9-a427-e9ce1d8e2179  Claim in safety — supported
    ├─ used  claim/65133798-94b5-4a5c-99a9-df54b7e32c64  Claim in safety — supported
    ├─ used  claim/35464e3c-e5a9-4c00-abc7-51c92afc589f  Claim in safety — supported
    ├─ used  claim/46380464-220b-458a-9deb-1a08fc960073  Claim in safety — supported
    ├─ used  claim/9c9b44c3-40f1-4708-953f-dcb19745c49e  Claim in safety — supported
    ├─ used  claim/cb10418a-3a99-4eae-8376-0636b8f0e62c  Claim in safety — supported
    ├─ used  claim/ade9d28b-e019-4243-8927-a4f049e0fba6  Claim in safety — inconclusive  working
    ├─ used  claim/f986e853-df02-4ef2-b557-904d372308a9  Claim in safety — supported
    ├─ used  claim/f36f7a75-9299-405a-93ad-380be3fd169d  Claim in safety — supported
      ├─ informed_by  section/summary.full@2
      ├─ informed_by  section/safety.full@2
      ├─ informed_by  section/alkaloid-profile.full@2
      ├─ informed_by  section/neuroscience.full@2
      ├─ informed_by  section/preparations.full@2
      ├─ informed_by  section/history.full@2
      └─ informed_by  section/botanical-overview.full@2

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2819 with DOI

3 strong · 22 moderate · 3 weak

Compilations

12026-05-14T06:54:30.081Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

23last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:32:18.114Z

notice · info card · emergency

Searches

240 with no results

queries and counts on the build

Claims checked

7838 supported

38 supported · 40 not

Correspondence

0received

consent field ships in Phase 4

Edges

244

derivations recorded for this entity

Complete over 28 sources, 1 compilation, and 23 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/hyoscyamus-niger/archive

2Build

one panel per compilation run

generation run 2026-05-14

82 min completedmodel pipeline-v5plan not recordedrun/ef13f8b0…

Selection

results seen116
selected by the model48
consumed as sources28

Verification

claims checked78
supported37
partially supported1
not supported0
inconclusive40
  • record
  • seen / partial
  • working

The model's own caveats

3 further caveats recorded as free text — readable on the working page

Reproduce

inputs
28 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
24 searches — query, source, results, what was kept and why
24 searches for this run
#sourcequeryseenkeptrationale
1PubChematropine11Atropine is the racemate of hyoscyamine; relevant to pharmacology
2PubMedHyoscyamus niger scopolamine hyoscyamine tropane alkaloids concentration134Ahmadpour provides H. niger-specific alkaloid concentrations; Hashimoto is key for biosynthesis
3PubChemscopolamine11Chemical identity verification for primary alkaloid
4OpenAlexHyoscyamus niger phytochemistry pharmacology153EFSA opinion and Swiss poisoning data are strong sources for safety section
5PubMedhenbane Hyoscyamus niger anticholinergic poisoning delirium hallucination11Key clinical toxicology reference for H. niger specifically
6PubMedscopolamine pharmacokinetics bioavailability half-life human83These provide pharmacokinetic data for the primary alkaloid scopolamine
7PubMedHyoscyamus niger review pharmacology alkaloids42Both highly relevant: Shim covers pharmacology/mechanism; Fatur & Kreft covers intoxication data for H. niger specifically
8PubChemhyoscyamine11Chemical identity verification for primary alkaloid
9PMC - PubMed CentralHyoscyamus niger alkaloid content toxic dose13Key quantitative data source for alkaloid content and dosing
10GoogleHyoscyamus niger history ancient Rome Vikings beer brewing103Historical/ethnobotanical use documentation for history section
11GoogleHyoscyamus niger legal status Europe UK Germany France scheduled controlled101Legal status data not findable via API tools
12USDA Forest ServiceHyoscyamus niger history traditional use13Authoritative USDA ethnobotany source on traditional uses
13ErowidHyoscyamus niger legal status12Primary legal status source for H. niger
14POWO - Plants of the World OnlineHyoscyamus niger taxonomy11Authoritative taxonomy database - provides accepted binomial and distribution
15PubMedscopolamine anticholinergic tolerance dependence withdrawal10No relevant results - gap noted for dependence data
16MultipleAlkaloid content comparison across H. niger plant sources43Synthesizes alkaloid quantification data across multiple H. niger studies
17WebSearchHyoscyamus niger Australia legal status101Australian legal status not clearly determinable from available sources
18DOI verification - CrossrefDOI 10.1016/j.toxicon.2020.02.005 and 10.2903/j.efsa.2013.338622DOI verification for key safety references
19PubMedHenbane chewing PMID 97979811Only documented case report of deliberate H. niger consumption for psychoactive effect
20PubMedscopolamine detection urine hair PMID 3703019911Documents detection windows for scopolamine in biological specimens
21Multiple primary sources cross-referenceSynthesis of H. niger safety, dose, and toxicology data86Core safety and toxicology data synthesis
22PMC/PubMedTeodorico Borgognoni anesthetic preparations medieval henbane PMID 3776331611Historical documentation of H. niger in medieval medical practice
23OpenAlexHyoscyamus niger henbane history traditional medicine ethnobotany103Ethnobotany and historical documentation sources
24WebSearchHyoscyamus niger noxious weed invasive status US states Canada101Legal status distinction between noxious weed and controlled substance
78 claims by section — every cited sentence, checked against its source
safety33 · 17 ok
  • Claim in safety — inconclusiveinconclusiveworking →

  • A retrospective analysis of 815 anticholinergic toxidrome patients found physostigmine associated with a lower intubation rate (1.9% vs 8.4%).supported

    Retrospective analysis of 815 anticholinergic toxidrome patients; physostigmine associated with lower intubation rate (1.9% vs 8.4%). s13181-014-0452-x

  • H. niger is a highly toxic plant; all parts — leaves, seeds, and roots — contain pharmacologically active tropane alkaloids.supported

    Black henbane (BH) or Hyoscyamus niger... Clinical manifestations of acute BH poisoning are very wide which include mydriasis, tachycardia, arrhythmia, agitation, convulsion and coma... pmid:25386392

  • H. niger is a highly toxic plant; all parts — leaves, seeds, and roots — contain pharmacologically active tropane alkaloids.supported

    Poisonous plants from Solanaceae family (Hyoscyamus niger...) are rich sources of tropane alkaloids. s13659-022-00357-w

  • The European Food Safety Authority (EFSA) established a group Acute Reference Dose (ARfD) of 0.016 µg/kg body weight (sum of hyoscyamine and scopolamine, assuming equal potency) based on decreased heart rate in a human volunteer study.supported

    Group ARfD of 0.016 µg/kg body weight established based on decreased heart rate in human volunteer study. j.efsa.2013.3386

  • Claim in safety — inconclusiveinconclusiveworking →

  • At severe doses: arrhythmia, convulsions, and coma.supported

    Clinical manifestations of acute BH poisoning are very wide which include... arrhythmia, agitation, convulsion and coma... pmid:25386392

  • The Swiss Toxicology Information Center documented 3 severe H. niger poisoning cases with anticholinergic syndrome among 152 total severe plant poisoning cases over a 29-year period (1966–1994) — compared with 42 cases for Atropa belladonna and 17 for Datura stramoniumsupported

    H. niger: 3 cases with anticholinergic syndrome among 152 severe plant poisoning cases in 29 years. Also documented: Atropa belladonna 42 cases, Datura stramonium 17 cases. pmid:8711457

  • A European review of anticholinergic Solanaceae intoxications (1966–2018) found that H. niger poisonings primarily result from the plant being mistaken for edible species; intentional use for psychoactive effect was substantially less common than for Daturasupported

    Datura stramonium, Atropa belladonna, Hyoscyamus niger, and Scopolia carniolica... H. niger was found to be largely ingested when mistaken for other plants. j.toxicon.2020.02.005

  • In Australia, a 1976 case report of deliberate henbane flower chewing noted "more widespread use of this plant among the drug-taking community," suggesting unreported cases.supported

    Case of deliberate chewing of henbane (Hyoscyamus niger) flowers to produce euphoria resulting in poisoning. Indicates use among drug-taking community in Australia. pmid:979798

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Elderly: Heightened anticholinergic sensitivity with significantly elevated risk of delirium; long-term anticholinergic exposure is associated with increased dementia risksupported

    Long-term anticholinergic exposure linked to dementia and neurodegenerative disease risk; mechanisms including vascular and neuroinflammatory pathways reviewed. jnc.15244

  • Claim in safety — inconclusiveinconclusiveworking →

  • The primary psychoactive effect of H. niger at doses achievable from plant material is delirium — an agitated, non-lucid state characterized by hallucinations and confusion that is not voluntarily controllablesupported

    Clinical manifestations of acute BH poisoning are very wide which include... auditory, visual or tactile hallucinations, confusion, disorientation, delirium, aggressiveness, and combative behavior. pmid:25386392

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • The following medication categories carry established anticholinergic properties that are additive with H. niger alkaloids:supported

    Overview of pharmacokinetic and pharmacodynamic herb-drug interactions; CYP enzyme induction/inhibition; additive and antagonistic effects. fphar.2012.00069

  • Claim in safety — inconclusiveinconclusiveworking →

  • A randomized trial found physostigmine superior to lorazepam for treatment of antimuscarinic toxidrome, and a prospective study from a regional poison center confirmed its superiority over non-antidote therapysupported

    Prospective investigation of physostigmine vs non-antidote therapy for antimuscarinic delirium in a regional poison center. 15563650.2018.1485154

  • Claim in safety — inconclusiveinconclusiveworking →

  • Elderly: Age-related increase in anticholinergic sensitivity; long-term exposure associated with dementia risksupported

    Long-term anticholinergic exposure linked to dementia and neurodegenerative disease risk; mechanisms including vascular and neuroinflammatory pathways reviewed. jnc.15244

  • Claim in safety — inconclusiveinconclusiveworking →

  • LC-MS/MS can detect both alkaloids in serum (limit of detection 0.02 ng/mL) and urine (170–670 ng/mL in clinical poisoning cases)supported

    LC/MS/MS method for hyoscyamine and scopolamine in serum/urine. Detection limit 0.02 ng/mL. In Datura poisoning cases: serum 0.45-3.5 ng/mL; urine 170-670 ng/mL. pmid:18787311

  • In a drug-facilitated sexual assault case, scopolamine was detected in urine at 41 µg/L at 18 hours post-exposure, and in hair at 0.37 pg/mg at 5 weeks post-exposure; blood was negative at 18 hourssupported

    Scopolamine detected in urine at 41 µg/L (18h post-exposure) and in hair at 0.37 pg/mg (5 weeks post-exposure) in DFSA case. Blood negative at 18h. j.forsciint.2023.111678

  • Claim in safety — inconclusiveinconclusiveworking →

  • Management: (1) supportive care as the mainstay; (2) activated charcoal if ingestion was recent and airway is protected — not ipecac; (3) benzodiazepines for agitation and seizure prevention; (4) physostigmine for severe anticholinergic delirium; (5) active temperature management for hyperthermia; (6) cardiac monitoring for arrhythmiasupported

    Physostigmine vs lorazepam comparison for antimuscarinic delirium and agitation treatment in clinical trial. 15563650.2020.1854281

  • Management: (1) supportive care as the mainstay; (2) activated charcoal if ingestion was recent and airway is protected — not ipecac; (3) benzodiazepines for agitation and seizure prevention; (4) physostigmine for severe anticholinergic delirium; (5) active temperature management for hyperthermia; (6) cardiac monitoring for arrhythmiasupported

    Prospective investigation of physostigmine vs non-antidote therapy for antimuscarinic delirium in a regional poison center. 15563650.2018.1485154

  • Claim in safety — inconclusiveinconclusiveworking →

alkaloid-profile12 · 7 ok
  • HPLC-DAD analysis of H. niger roots under optimized ultrasound-assisted extraction yielded hyoscyamine at 164.72 µg/g dry weight and scopolamine at 209.23 µg/g dry weight, confirming that scopolamine exceeds hyoscyamine in root tissuesupported

    The optimal extraction yielded hyoscyamine 164.72 µg/g dry weight and scopolamine 209.23 µg/g dry weight from H. niger roots. j.heliyon.2024.e38856

  • Wild-type hairy root cultures produced hyoscyamine at approximately 54 µg/g dry weight as a baseline reference.supported

    Wild-type H. niger hairy roots baseline data: hyoscyamine ~54 µg/g. s41598-018-36156-y

  • Three minor tropane alkaloids have been confirmed in H. niger. Anisodamine has been identified by HPLC. Cuscohygrine occurs primarily in roots, reaching 26.5 mg/g dry weight in hairy root bioreactor cultures. Apoatropine is present in whole-plant preparationssupported

    Scopolamine, hyoscyamine and cuscohygrine concentrations were highest in the bubble-column reactor (5.3, 1.6 and 26.5 mg/g dry wt, respectively). Also detected: anisodamine. s10529-013-1426-9

  • Three minor tropane alkaloids have been confirmed in H. niger. Anisodamine has been identified by HPLC. Cuscohygrine occurs primarily in roots, reaching 26.5 mg/g dry weight in hairy root bioreactor cultures. Apoatropine is present in whole-plant preparationssupported

    Anisodamine and scopolamine are both found in H. niger. HnArAT3 gene involved in phenyllactic acid branch of TA biosynthetic pathway. pmid:29911833

  • Three minor tropane alkaloids have been confirmed in H. niger. Anisodamine has been identified by HPLC. Cuscohygrine occurs primarily in roots, reaching 26.5 mg/g dry weight in hairy root bioreactor cultures. Apoatropine is present in whole-plant preparationssupported

    Scopolamine, hyoscyamine and cuscohygrine concentrations were highest in the bubble-column reactor (5.3, 1.6 and 26.5 mg/g dry wt, respectively). Also detected: anisodamine. s10529-013-1426-9

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • The terminal step is catalyzed by hyoscyamine 6β-hydroxylase (H6H), a 2-oxoglutarate-dependent dioxygenase first purified and characterized from H. niger root culturessupported

    Hyoscyamine 6 beta-hydroxylase, a 2-oxoglutarate-dependent dioxygenase that catalyzes the hydroxylation of l-hyoscyamine to 6 beta-hydroxyhyoscyamine in the biosynthetic pathway leading to scopolamine. pmid:3569262

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • The complete biosynthetic pathway from amino acid precursors to scopolamine has been reconstructed in yeast, confirming each enzymatic step.supported

    Complete biosynthesis of hyoscyamine and scopolamine reconstructed in yeast; full pathway from amino acids to final alkaloids established. s41586-020-2650-9

preparations11 · 3 ok
  • For reference, pharmaceutical transdermal scopolamine patches deliver 0.5 mg over 72 hours from a 1.5 mg reservoir.supported

    TTS-patch delivers 0.5 mg over 72h. pmid:16175141

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Claim in preparations — inconclusiveinconclusiveworking →

  • One documented case of deliberate henbane flower chewing in an adult resulted in acute anticholinergic poisoning.supported

    Case of deliberate chewing of henbane (Hyoscyamus niger) flowers to produce euphoria resulting in poisoning. pmid:979798

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Contamination of commercial herbal teas by H. niger seeds has been documented as a food safety concernsupported

    Routes of intentional and unintentional tropane alkaloid poisoning reviewed. Concentrations highest in roots and seeds. qas2013.0314

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Claim in preparations — inconclusiveinconclusiveworking →

neuroscience10 · 4 ok
  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Hyoscyamine and scopolamine are competitive, non-selective muscarinic acetylcholine receptor (mAChR) antagonists, blocking the neurotransmitter acetylcholine at M1, M2, and M3 receptor subtypes in both the central and peripheral nervous system.supported

    These compounds possess the anticholinergic properties as they could block the neurotransmitter acetylcholine action in the central and peripheral nervous system by binding at either muscarinic and/or nicotinic receptors. s13659-022-00357-w

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Scopolamine (oral): Bioavailability 3–27%, highly variable between individualssupported

    Oral bioavailability 3-27%. pmid:16175141

  • Tmax approximately 0.5 hourssupported

    The maximum drug concentration occurs approximately 0.5 hours after oral administration. pmid:16175141

  • Plasma half-life 4.5 ± 1.7 hourssupported

    After IV, elimination half-life 4.5±1.7 hr. pmid:2762223

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

summary7 · 3 ok
  • It is classified as a deliriant — its pharmacology is driven by the tropane alkaloids scopolamine and hyoscyamine, which produce anticholinergic toxidrome at doses readily achievable from crude plant materialsupported

    Poisonous plants from Solanaceae family (Hyoscyamus niger...) are rich sources of tropane alkaloids. These compounds possess the anticholinergic properties as they could block the neurotransmitter acetylcholine action in the central and peripheral nervous system. s13659-022-00357-w

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Oral bioavailability of purified scopolamine ranges from 3–27% with a plasma half-life of approximately 4.5 hours; no pharmacokinetic data exist for crude plant preparations.partially supported

    After IV, elimination half-life 4.5±1.7 hr. Oral bioavailability variable, range 10.7-48.2%. pmid:2762223

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Physostigmine, a cholinesterase inhibitor, is the specific antidote for severe anticholinergic toxidromesupported

    Physostigmine vs lorazepam comparison for antimuscarinic delirium and agitation treatment in clinical trial. 15563650.2020.1854281

history3 · 2 ok
  • Teodorico Borgognoni (1205–1296) included narcotic plants — likely including henbane — in his anesthetic preparations documented in Cyrurgia seu filia principissupported

    Medieval anesthetic preparations including narcotic plants; Teodorico Borgognoni (13th century) used henbane-containing preparations as anesthetics. life13091913

  • Contemporary ethnobotanical surveys document continued traditional medicinal use of H. niger in Morocco among High Atlas Tashelhit-speaking communitiessupported

    Ethnomedicinal survey documenting traditional plant use including Hyoscyamus niger in High Atlas Moroccan communities. j.jep.2016.05.009

  • Claim in history — inconclusiveinconclusiveworking →

botanical-overview2 · 2 ok
  • Some cultivation for pharmaceutical alkaloid production has been documented, though commercial-scale tropane alkaloid production has largely shifted to hybrid Duboisia cropssupported

    Commercial-scale alkaloid production from Duboisia hybrid crops; tissue-specific distribution of hyoscyamine, scopolamine and precursors. pcx165

  • Morphological distinctiveness reduces the risk of deliberate product adulteration, but accidental misidentification with edible umbellifers, beets, and garden herbs has been documented in poisoning literaturesupported

    H. niger was found to be largely ingested when mistaken for other plants. j.toxicon.2020.02.005

3Sources

28 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
2024Ultrasound-assisted extraction of scopolamine and hyoscyamine from Hyoscyamus niger roots using central compost designAhmadpour R, Zanjani BM, Garoosi GA, Farjaminezhad R, Haddad R · Heliyondoi:10.1016/j.heliyon.2024.e38856moderateconsumed1 section
2023Detection of scopolamine in urine and hair in a drug-facilitated sexual assaultMelchior SE, Nielsen MKK, Oropeza AR, Banner J, Johansen SS · Forensic Science Internationaldoi:10.1016/j.forsciint.2023.111678weakconsumed1 section
2023Teodorico Borgognoni's Formulary for Thirteenth Century Anesthetic PreparationsCavalloro V, Soddu F, Baroni S, et al. · Life (Basel)doi:10.3390/life13091913moderateconsumed1 section
2022Beauty of the beast: anticholinergic tropane alkaloids in therapeuticsShim KH, Kang MJ, Sharma N, An SSA · Natural Products and Bioprospectingdoi:10.1007/s13659-022-00357-wmoderateconsumed4 sections
2021A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidromeWang GS, Baker K, Ng P, et al. · Clinical Toxicologydoi:10.1080/15563650.2020.1854281moderateconsumed2 sections
2021Nixing the nightshades: Traditional knowledge of intoxicating members of the Solanaceae among hallucinogenic plant and mushroom users in SloveniaFatur K, Kreft S · PLoS ONEdoi:10.1371/journal.pone.0247688moderateconsumed2 sections
2021Tardive neurotoxicity of anticholinergic drugs: A reviewMarzoughi S, Banerjee A, Jutzeler CR, et al. · Journal of Neurochemistrydoi:10.1111/jnc.15244moderateconsumed1 section
2020Biosynthesis of medicinal tropane alkaloids in yeastSrinivasan P, Smolke CD · Naturedoi:10.1038/s41586-020-2650-9moderateconsumed1 section
2020Common anticholinergic solanaceaous plants of temperate Europe - A review of intoxications from the literature (1966-2018)Fatur K, Kreft S · Toxicondoi:10.1016/j.toxicon.2020.02.005strongconsumed2 sections
2019Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison centerBoley SP, Olives TD, Bangh SA, Fahrner S, Cole JB · Clinical Toxicologydoi:10.1080/15563650.2018.1485154moderateconsumed1 section
2018Localization and Organization of Scopolamine Biosynthesis in Duboisia myoporoides R. Br.Kohnen KL, Sezgin S, Spiteller M, Hagels H, Kayser O · Plant and Cell Physiologydoi:10.1093/pcp/pcx165moderateconsumed1 section
2018Targeted expression of Vitreoscilla hemoglobin improves the production of tropane alkaloids in Hyoscyamus niger hairy rootsGuo Z, Tan H, Lv Z, et al. · Scientific Reportsdoi:10.1038/s41598-018-36156-ymoderateconsumed1 section
2017Cloning and characterization of an aromatic amino acid aminotransferase (ArAT) gene involved in tropane alkaloid biosynthesis from Hyoscyamus nigerLi X, Qiang W, Qiu F, et al. · Acta Pharmaceutica Sinicapmid:29911833moderateconsumed1 section
2016An ethnomedicinal survey of a Tashelhit-speaking community in the High Atlas, MoroccoTeixidor-Toneu I, Martin GJ, Ouhammou A, Puri RK, Hawkins JA · Journal of Ethnopharmacologydoi:10.1016/j.jep.2016.05.009moderateconsumed1 section
2015The Use of Physostigmine by Toxicologists in Anticholinergic Toxicity.Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME · Journal of Medical Toxicologydoi:10.1007/s13181-014-0452-xmoderateconsumed1 section
2014Black henbane and its toxicity - a descriptive reviewAlizadeh A, Moshiri M, Alizadeh J, Balali-Mood M · Avicenna Journal of Phytomedicinepmid:25386392strongconsumed5 sections
2014Production of tropane alkaloids in Hyoscyamus niger (black henbane) hairy roots grown in bubble-column and spray bioreactorsJaremicz Z, Luczkiewicz M, Kokotkiewicz A, Krolicka A, Sowinski P · Biotechnology Lettersdoi:10.1007/s10529-013-1426-9moderateconsumed1 section
2014Tropane alkaloids in food: poisoning incidentsAdamse P, van Egmond HP, Noordam MY, Mulder P, de Nijs M · Quality Assurance and Safety of Crops & Foodsdoi:10.3920/qas2013.0314weakconsumedcited only
2013Scientific Opinion on Tropane Alkaloids in Food and FeedEFSA Panel on Contaminants in the Food Chain (CONTAM) · EFSA Journaldoi:10.2903/j.efsa.2013.3386moderateconsumed2 sections
2012An Overview of the Evidence and Mechanisms of Herb-Drug InteractionsFasinu PS, Bouic P, Rosenkranz B · Frontiers in Pharmacologydoi:10.3389/fphar.2012.00069moderateconsumed1 section
2008Determination of hyoscyamine and scopolamine in serum and urine of humans by liquid chromatography with tandem mass spectrometryKonishi T, Akaki K, Hatano K · Journal of the Food Hygienic Society of Japanpmid:18787311moderateconsumed1 section
2005Pharmacokinetics and pharmacodynamics in clinical use of scopolamineRenner UD, Oertel R, Kirch W · Therapeutic Drug Monitoringpmid:16175141moderateconsumed5 sections
2001Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteersEbert U, Grossmann M, Oertel R, Gramatte T, Kirch W · Journal of Clinical Pharmacologypmid:11144994moderateconsumed1 section
1999Medicinal Plants and Alzheimer's Disease: from Ethnobotany to PhytotherapyPerry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS · Journal of Pharmacy and Pharmacologydoi:10.1211/0022357991772808moderateconsumedcited only
1996Serious plant poisonings in Switzerland 1966-1994. Case analysis from the Swiss Toxicology Information CenterJaspersen-Schib R, Theus L, Guirguis-Oeschger M, Gossweiler B, Meier-Abt PJ · Schweizerische Medizinische Wochenschriftpmid:8711457moderateconsumed1 section
1989Pharmacokinetics and oral bioavailability of scopolamine in normal subjectsPutcha L, Cintrón NM, Tsui J, Vanderploeg JM, Kramer WG · Pharmaceutical Researchpmid:2762223strongconsumed2 sections
1987Purification and characterization of hyoscyamine 6 beta-hydroxylase from root cultures of Hyoscyamus niger L.Hashimoto T, Yamada Y · European Journal of Biochemistrypmid:3569262moderateconsumed1 section
1976Henbane chewingSands JM, Sands R · Medical Journal of Australiapmid:979798weakconsumed2 sections

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-03-17importImported from Curiosity v1

    imported 2026-03; original sourcing not recoverable

    psx:substance/hyoscyamus-niger/import/curiosity-v1
  2. 0022026-03-17publicationPublication — backfill
  3. 0032026-03-17revisionRevision 1
  4. 0042026-05-14revisionRevision 2

    Initial LLM generation (plant pipeline v1, wiki, prose phase)

    psx:substance/hyoscyamus-niger/version/2
  5. 0052026-06-04proposal18 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    18 items in this filing

    • contraindication · pregnancy_breastfeeding
    • contraindication · age
    • contraindication · cardiovascular
    • contraindication · renal
    • contraindication · other
    • contraindication · hepatic
    • contraindication · psychiatric
    • contraindication · age
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    psx:substance/hyoscyamus-niger/proposal/contraindication/0ae6b0ed-6c93-4672-8a5a-c24a833f9a33
  6. 0062026-06-04publicationPublication — backfill

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergency202c57e4fe575e44059df0ab…2026-10-19 20:32Revision 2current
info_carddc0cc18f30b207b33d7785d4…2026-10-19 20:32Revision 2current
emergencye2acd002694f8aad19cda75f…2026-09-04 04:30Revision 2superseded2026-10-19
info_card1fb004e05d184ec8363725b7…2026-09-04 04:30Revision 2superseded2026-10-19
noticef56c8fd9c2e621c56e23833a…2026-09-04 04:30Revision 2current